Trial Profile

First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary) ; Ciclosporin; Ciclosporin; Methylprednisolone; Prednisolone
Indications Haemophagocytic lymphohistiocytosis
Focus Therapeutic Use

Most Recent Events

10 Dec 2019 Results of a retrospective analysis of 26 patients (pilot study) and prospective analysis of 29 enrolled patients presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
10 Dec 2019 Status changed to completed, according to the results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
20 Dec 2017 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com